Source-grounded facts extracted from JUPITER NEUROSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Allison W. Brady resigned as Member of the Board of Directors at JUPITER NEUROSCIENCES, INC..
“On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective immediately.”
Alison Silva was appointed as Chief Operating Officer and President at JUPITER NEUROSCIENCES, INC..
“The Amendment appoints Ms. Silva as the Company’s Chief Operating Officer and President”
JUPITER NEUROSCIENCES, INC. entered into Placement Agent Agreement with D. Boral Capital LLC valued at 7.0% of the gross proceeds (effective 2026-05-20).
“On May 20, 2026, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with D. Boral Capital LLC (“D. Boral”) pursuant to which the Company engaged D. Boral as the placement agent (the “Placement Agent”) in connection with the Offering.”
JUPITER NEUROSCIENCES, INC. entered into Securities Purchase Agreement with the investors named therein valued at approximately $2.0 million (effective 2026-05-20).
“On May 20, 2026, Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), 7,142,858 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”), at a price of $0.28 per share, for aggregate gross proceeds to the Company of approximately $2.0 million before deducting the placement agent’s fees and related offering expenses.”
JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bid price requirement (the “ Minimum Bid Price Requirement ”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price”
JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 26, 2026, Jupiter Neurosciences, Inc. (the “ Company ”) received two written notices (each, a “ Notice ” and together, the “ Notices ”) from the Listing Qualifications Department of Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that (i) the listing of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) was not in compliance with the minimum bid price requirement (the “ Minimum Bid Price Requirement ”) as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price”
JUPITER NEUROSCIENCES, INC. amended Omnibus Amendment with YA II PN, LTD (effective 2026-02-20).
“On February 20, 2026, the Company and Yorkville entered into an Omnibus Amendment (the “Amendment”) to revise Section 1(c) of the A&R Convertible Notes, the “Monthly Payments” provision.”
JUPITER NEUROSCIENCES, INC. entered into SEPA with Yorkville.
“he SEPA, Yorkville represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act).”
JUPITER NEUROSCIENCES, INC. issued convertible note to YA II PN, LTD for $3,720,000.
“the first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October 27, 2025, in exchange for the Company’s issuance to Yorkville of a Convertible Note in the principal amount of $4.0 million”
JUPITER NEUROSCIENCES, INC. issued common stock to YA II PN, LTD for up to $20.0 million.
“the Company has the right to sell to Yorkville up to $20.0 million of its common stock”
JUPITER NEUROSCIENCES, INC. incurred convertible notes of $4.0 million with YA II PN, LTD.
“The first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October 27, 2025, in exchange for the Company’s issuance to Yorkville of a Convertible Note in the principal amount of $4.0 million, which was issued with an “original issue discount” (“OID”) of 7.0% (or $280,000) and is initially convertible into Common Stock at a fixed conversion price of $1.50 per share (subject to adjustment as provided in such Convertible Note) (the “First Convertible Note”).”
JUPITER NEUROSCIENCES, INC. engaged Cherry Bekaert LLP as its auditor.
“Concurrent with such resignation, the Audit Committee of the Board of Directors of the Company approved the engagement of Cherry Bekaert LLP ("CB") as the new independent registered public accounting firm for the Company, effective as of April 16, 2025.”
Assurance Dimensions, LLC resigned as auditor of JUPITER NEUROSCIENCES, INC..
“Assurance Dimensions, LLC ("AD"), the independent registered public accounting firm for Jupiter Neurosciences, Inc. advised the Company that it was resigning as the independent registered accounting for the Company, effective as of April 16, 2025, as a result of its decision to discontinue its PCAOB registrants practice.”
JUPITER NEUROSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 21, 2025, Jupiter Neurosciences, Inc. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ. Listing Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $1.00 USD per share for its securities listed on the NASDAQ, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficie”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.